Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Accumulated Expenses (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Accumulated Expenses for 10 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 72.1% year-over-year to $5.6 million, compared with a TTM value of $5.6 million through Sep 2025, up 72.1%, and an annual FY2024 reading of $17.7 million, up 170.31% over the prior year.
  • Accumulated Expenses was $5.6 million for Q3 2025 at Spero Therapeutics, down from $6.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $17.7 million in Q4 2024 and bottomed at $2.4 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $7.5 million, with a median of $6.6 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses crashed 81.5% in 2022, then skyrocketed 170.31% in 2024.
  • Year by year, Accumulated Expenses stood at $5.9 million in 2021, then soared by 52.5% to $9.0 million in 2022, then fell by 26.93% to $6.6 million in 2023, then surged by 170.31% to $17.7 million in 2024, then plummeted by 68.16% to $5.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for SPRO at $5.6 million in Q3 2025, $6.7 million in Q2 2025, and $4.9 million in Q1 2025.